Close Menu

peripheral artery disease

Through a genome-wide association study, a team of researchers from Riken uncovered three loci linked to peripheral artery disease susceptibility.

On a conference call last month following the release of its Q1 earnings, Vermillion CEO Thomas McLain announced that the company would be taking over from Quest Diagnostics as leader of commercialization efforts for its OVA1 ovarian cancer diagnostic (

Vermillion this week sent Quest Diagnostics a notice of default under the companies' Strategic Alliance Agreement relating to Vermillion's OVA1 and Vasclir diagnostic tests.

This story has been update to include comments from a Vermillion executive.

Vermillion this week reported essentially flat revenues for the third quarter of 2012 compared to the year-ago period.

This article has been updated from a version posted Oct. 12 to include additional information.

Vermillion last week reported results demonstrating the utility of its Vasclir protein biomarker test for peripheral artery disease.

This story originally ran on May 16.
Vermillion this week reported first-quarter 2012 revenues of $312,000, down 28 percent from $431,000 a year ago.

This story originally ran on Feb. 29 and has been updated to include comments from an investor.
By Adam Bonislawski

This story originally ran on Jan. 4 and has been updated to include additional information about company restructuring.

Pages

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.